Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

被引:565
作者
Gisbert, Javier P. [1 ]
Panes, Julian [2 ]
机构
[1] Hosp Univ Princesa, Dept Gastroenterol, Madrid, Spain
[2] Hosp Clin Barcelona, Dept Gastroenterol, Barcelona, Spain
关键词
NECROSIS-FACTOR-ALPHA; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE INFLIXIMAB; CLINICAL-EXPERIENCE; EPISODIC TREATMENT; SHORT-TERM; THERAPY; EFFICACY; ANTIBODY; PREDICTORS;
D O I
10.1038/ajg.2008.88
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: To review the frequency with which infliximab loses its effect and dose "intensification" is required for Crohn's disease treatment. METHODS: Bibliographical searches were performed in MEDLINE, and European (ECCO) and American (DDW) Congresses. Studies evaluating loss of efficacy and requirement of infliximab dose intensification-defined either as an increase of the infliximab dose (generally from 5 mg/kg to 10 mg/kg) or as a decrease in the frequency of infusion (to as often as every 4 weeks)-in Crohn's disease patients were included. RESULTS: Sixteen studies evaluating the incidence of loss of response to infliximab in Crohn's disease patients were found. A total of 2,236 patients were included (the majority of them receiving a three-dose induction regimen at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks), providing 6,284 patient-years of follow-up. The mean percentage of patients with loss of infliximab response was 37%. However, as the follow-up time varied markedly among studies, the risk of losing response to infliximab is better expressed as the incidence of this complication per patient-year of follow-up. Therefore, the annual risk for loss of infliximab response was calculated to be 13% per patient-year. CONCLUSIONS: A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients-more than 10% per patient-year of infliximab treatment-on long term will lose response and will require an increase in dose and/or decrease in infusion interval.
引用
收藏
页码:760 / 767
页数:8
相关论文
共 49 条
[1]   Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease [J].
Ainsworth, Mark A. ;
Bendtzen, Klaus ;
Brynskov, Jorn .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) :944-948
[2]   An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease [J].
Arnott, IDR ;
McNeill, G ;
Satsangi, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1451-1457
[3]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[4]  
Baert F, 2007, ACTA GASTRO-ENT BELG, V70, P163
[5]   Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease [J].
Candon, S ;
Mosca, A ;
Ruemmele, F ;
Goulet, O ;
Chatenoud, L ;
Cézard, JP .
CLINICAL IMMUNOLOGY, 2006, 118 (01) :11-19
[6]  
Chaparro M, 2008, GASTROENTEROLOGY, V134, pA664
[7]   American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006 [J].
Clark, M. ;
Colombel, J.-F. ;
Feagan, B. C. ;
Fedorak, K. N. ;
Hanauer, S. B. ;
Kamm, M. A. ;
Mayer, L. ;
Regueiro, C. ;
Rutgeerts, P. ;
Sandborn, W. J. ;
Sands, B. E. ;
Schreiber, S. ;
Targan, S. ;
Travis, S. ;
Vermeire, S. .
GASTROENTEROLOGY, 2007, 133 (01) :312-339
[8]  
Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469
[9]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[10]   Escalation of infliximab maintenance therapy in Crohn's disease [J].
Corman, Scott ;
Issa, Mazen ;
Beaulieu, Dawn B. ;
Weber, Lydia R. ;
Brandenburg, Heather ;
Emmons, Jeanne ;
Knox, Josh F. ;
Skaros, Sue ;
Thameem, Danish ;
Binion, David G. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09) :S470-S470